Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
22 janv. 2018 18h59 HE
|
Histogenics Corporation
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...
Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
09 janv. 2018 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
21 déc. 2017 06h00 HE
|
Histogenics Corporation
– Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales ‒ ‒ Japanese Cartilage Repair Market is Large and Growing...
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
09 nov. 2017 06h30 HE
|
Histogenics Corporation
Top-line, 1-year Superiority Data for NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 Company to Host Conference Call...
Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
26 oct. 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
12 oct. 2017 09h00 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the...
Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
02 oct. 2017 16h15 HE
|
Histogenics Corporation
– Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to...
Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
26 sept. 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the...
Histogenics Corporation to Present at Upcoming Investor Conferences
24 août 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
10 août 2017 06h30 HE
|
Histogenics Corporation
‒ Completed Enrollment in NeoCart® Phase 3 Clinical Trial ‒‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒‒ Defined Regulatory Pathway with Japan Pharmaceuticals and...